Foscarnet sodium for treatment in patients with severe chronic hepatitis B.
- Author:
Yan-yan YU
1
;
Da-zhi ZHANG
;
Xiao-hui MIAO
;
Chuan-lin ZHU
;
Xia-qiu ZHOU
;
Hao YU
;
Chong-wen SI
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Antiviral Agents; adverse effects; therapeutic use; Double-Blind Method; Female; Foscarnet; adverse effects; therapeutic use; Hepatitis B, Chronic; drug therapy; Humans; Male; Middle Aged; Young Adult
- From: Chinese Journal of Hepatology 2006;14(11):814-816
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effectiveness of foscarnet sodium in the treatment of severe chronic hepatitis B.
METHODSTwo hundred and eight patients were enrolled in a multicenter, double-blind, controlled study. The patients received foscarnet sodium (foscarnet group) or saline (control group) injections for 4 weeks, and were then followed for 24 weeks.
RESULTSHBV DNA negative rate was 12.8% in the foscarnet group and 7.1% in the control group at the end of treatment; and it was 5.5% and 3.0% at the end of the follow-up period respectively (P > 0.05). The rate of HBV DNA decrease of more than 2 log copies/ml was 53.2% in the foscarnet group and 16.2% in the control group at the end of treatment, and 23.9% and 8.1% (P < 0.01) respectively at the end of the follow-up period. The rate of HBV DNA < 10(5) copies/ml was 64.2% and 30.3% at week 4 in the two groups respectively, and 40.4% and 22.2% (P < 0.01) at the end of the follow-up period. HBeAg negative rate was 17.3% and 5.8% at the end of the treatment, and 22% and 5.4% at the end of the follow-up period (P < 0.01). The rate of HBeAg seroconversion was 12.7% and 3.7% at week 4, and 16.7% and 1.5% at the end of the follow-up period. Response rate was 60.6% and 21.2% at the end of week 4 (P < 0.05).
CONCLUSIONFoscarnet sodium injection has a good effect on severe chronic hepatitis B patients and it is safe to use on them.
